Skip to main content

Advertisement

SpringerLink
Log in

Moderne immuntherapeutische Ansätze für die Behandlung von Lungen- und Kopf-Hals-Tumoren

Modern Immunotherapeutic Approaches to Cancers of the Lung and Head and Neck

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Multimodale Therapiestrategien, die Chirurgie, Strahlen- und Chemotherapie kombinieren, haben die Behandlungsergebnisse bei Tumoren der Lunge und der Kopf-Hals Region verbessert. Die Ergänzung des Therapiespektrums um weitere Ansätze, die sich in der Wirkungsweise und möglichst durch reduzierte Toxizität von den konventionellen unterscheiden, erscheint jedoch zur Erzielung weiterer Fortschritte notwendig. Eine neue Generation immunologischer passiver (antikörperbasierter) und auch aktiver (Vakzinierungs-) Strategien erscheint aussichtsreich und befindet sich gegenwärtig in der klinischen Prüfung. Die Untersuchung der optimalen zeitlichen Sequenz in Kombination mit den konventionellen Therapieverfahren und die Individualisierung der Therapie auf Basis genomischer/proteomischer Daten muss die klinische Integration begleiten.

Abstract

Multimodal therapy strategies combining surgery and both radio- and chemotherapy have improved treatment results for patients with tumors of the lung and of the head and neck region. It seems, however, that it will benecessary to supplement conventional therapy with innovative approaches that have different mechanisms of action and different toxicities for further progress to be achieved. A new generation of both passive (antibody-based) and active (vaccination) immune therapy strategies seems promising and is currently in the clinical trial stage. Integration of these strategies into clinical practice must be accompanied by investigation of the optimal sequencing of conventional and new therapies and their tailoring on the basis of genomic and proteomic data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. 6. Internationale Konferenz für Kopf-Hals Tumoren. Washington DC, 2004

  2. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360

    Google Scholar 

  3. Baumann M, Krause M (2004) Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72:257–266

    Google Scholar 

  4. Berinstein N (2003) Overview of therapeutic vaccination approaches for cancer. Semin Oncol 30:1–8

    Google Scholar 

  5. Bonner JA, Harari PM, Giralt J, Azarnia N, Cohen RB, Raben D, Jones C, Kies MS, Baselga J, Ang KK (2004) Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol (Meeting Abstracts) 22:5507

    Google Scholar 

  6. Borjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA (2003) Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9:3961S–3972S

    Google Scholar 

  7. Bunn PA Jr (1999) Immune therapy for lung cancer: are we getting closer? Am J Respir Cell Mol Biol 21:10–12

    Google Scholar 

  8. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980–1987

    Google Scholar 

  9. Cohen S, Carpenter G, King L Jr (1980) Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255:4834–4842

    Google Scholar 

  10. Cowley GP, Smith JA, Gusterson BA (1986) Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer 53:223–229

    Google Scholar 

  11. Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K (2004) ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7083

    Google Scholar 

  12. Crombet T, Neninger E, Osorio M, Catala M, Torre A, Leonard I, Garcia B, Gonzalez G, Perez R, Lage A (2004) Vaccination with epidermal growth factor (EGF) for non small cell lung cancer (NSCLC) therapy: Preliminary results from a randomized phase II clinical trial. J Clin Oncol (Meeting Abstracts) 22:2514

    Google Scholar 

  13. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernandez E, Alvarez D, Torres O, Ramos M, Leonard I, Perez R, Lage A (2004) Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22:1646–1654

    Google Scholar 

  14. Dazzi H, Hasleton PS, Thatcher N, Barnes DM, Wilkes S, Swindell R, Lawson RA (1989) Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 59:746–749

    Google Scholar 

  15. Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC (1996) Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol 157:1406–1414

    Google Scholar 

  16. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V (2004) Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15:19–27

    Google Scholar 

  17. Gaudernack G, Buanes T, Meo M, Aamdal S, Brunsvig P, Braathen LR, Kernland K, Gjertsen MK, Eriksen JA, Moller M (2003) Clinical trials of a peptide based vaccine targeting telomerase. Proc Am Soc Clin Oncol (Meeting Abstracts) 22:166

    Google Scholar 

  18. Giaccone G, Debruyne C, Felip E, Millward M, D’Addario G, Thiberville L, Rome L, Zatloukal P, Legrand C (2004) Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). J Clin Oncol (Meeting Abstracts) 22:7020

    Google Scholar 

  19. Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199:251–263

    Google Scholar 

  20. Gonzalez G, Viada C, Neninger E, Crombet T, Leonard I, Garcia B, Lage A (2004) Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials. J Clin Oncol (Meeting Abstracts) 22:2548

    Google Scholar 

  21. Hadden J, Verastegui E, Barrera JL, Kurman M, Meneses A, Zinser JW, de la Garza J, Hadden E (2003) A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacol 3:1073–1081

    Google Scholar 

  22. Hege KM, Carbone DP (2003) Lung cancer vaccines and gene therapy. Lung Cancer 41 [Suppl 1]: S103–113

    Google Scholar 

  23. Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ (2004) A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 10:4363–4368

    Google Scholar 

  24. Herbst RS, Sandler AB (2004) Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 9 [Suppl 1]:19–26

    Google Scholar 

  25. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M (2000) Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 161:589–594

    Google Scholar 

  26. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J (2004) Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 22:2808–2815

    Google Scholar 

  27. Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jager D, Renner C, Tanswell P, Kunz U, Amelsberg A, Kuthan H, Stehle G (2003) Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26:44–48

    Google Scholar 

  28. Hoos A (2004) The promise of Cancer Vaccines. Drug Discovery Develop 13

    Google Scholar 

  29. Ishioka GY, Disis ML, Morse MA, Cunningham CC, Lenz H-J, Figlin RA, Chesnut RW, Fikes J (2004) A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients. J Clin Oncol (Meeting Abstracts) 22:2525

    Google Scholar 

  30. Korst RJ, Crystal RG (2003) Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification. Ann Thorac Surg 76:1319–1326

    Google Scholar 

  31. Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO (2004) Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10:6094–6100

    Google Scholar 

  32. Leichman G, Gravenor D, Albert G, Schmalbach T (2004) A TLR9 CpG immunomodulator in combination with chemotherapy as treatment for advanced non-small cell lung cancer (NSCLS), a randomized, controlled phase II study. J Clin Oncol (Meeting Abstracts) 22:7126

    Google Scholar 

  33. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101 [Suppl 2]:14567–14571

    Google Scholar 

  34. Loibner H, Eckert H, Eller N, Groiss F, Himmler G, Rosenkaimer F, Salzberg M, Samonigg H, Schuster M, Settaf A (2004) A randomized placebo-controlled phase II study with the cancer vaccine IGN101 in patients with epithelial solid organ tumors (IGN101/2–01). J Clin Oncol (Meeting Abstracts) 22:2619

    Google Scholar 

  35. Lynch TJ, Lilenbaum R, Bonomi P, Ansari R, Govindan R, Janne PA, Hanna N (2004) A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7084

    Google Scholar 

  36. Mason KA, Neal R, Hunter NR, Ariga H, Krieg AM, Whisnant JK, Milas L (2004) CpG oligodeoxynucleotide (ODN) is a potent enhancer of fractionated radiotherapy. J Clin Oncol (Meeting Abstracts) 22:3113

    Google Scholar 

  37. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM, Whisnant JK (2004) CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64:5074–5077

    Google Scholar 

  38. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19:3159–3167

    Google Scholar 

  39. Port Metaanalysis Group (1998) Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 352:257–263

    Google Scholar 

  40. Ribas A, Butterfield LH, Glaspy JA, Economou JS (2003) Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21:2415–2432

    Google Scholar 

  41. Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B (2003) Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5:690–699

    Google Scholar 

  42. Rosell R, Daniel C, Ramlau R, Szczesna A, Constenla M, Mennecier B, Pfeifer W, Mueser M, Montaner I, Gatzemeier U (2004) Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7012

    Google Scholar 

  43. Ross HJ, Rudin CM, Hart LL, Swanson PM, Rarick MU, Figlin RA, Jacobs AD, Miller DM (2004) Randomized phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 22:7039

    Google Scholar 

  44. Sandler AB, Blumenschein GR, Henderson T, Lee J, Truong M, Kim E, Mass B, Garcia B, Johnson DH, Herbst RS (2004) Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. J Clin Oncol (Meeting Abstracts) 22:2000

    Google Scholar 

  45. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Google Scholar 

  46. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ (2003) A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639–1647

    Google Scholar 

  47. Sette A, Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15:461–470

    Google Scholar 

  48. Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M, Stamatis G, Passlick B (2004) Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 25:131–134

    Google Scholar 

  49. Squiban P, Velu T, Mennecier B, Pless M, Morel V, Levy E, Richard V, Maciejewska T, Bizouarne N, Quoix E (2004) MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data. J Clin Oncol (Meeting Abstracts) 22:2544

    Google Scholar 

  50. Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4:397–406

    Google Scholar 

  51. Stratton MR, Futreal PA (2004) Cancer: understanding the target. Nature 430:30

    Google Scholar 

  52. Talor E, Timar J, Repassy G, Szabo G, Remenar E, Balatoni Z, Zemplen B (2004) Leukocyte interleukin, injection (LI) treatment in advanced primary squamous cell carcinoma of the head & neck a phase II multi-center trial and pathology study. J Clin Oncol (Meeting Abstracts) 22:2605

    Google Scholar 

  53. Tanovic A, Alfaro V (2004) Gefitinib: current status in the treatment of non-small cell lung cancer. Drugs Today (Barc) 40:809–827

    Google Scholar 

  54. Tolcher AW, Mita M, Patnaik A, Rowinsky EK, Corey A, Fleming M, Fox NL, Weiner LM, Meropol NJ, Cohen R (2004) A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 22:3060

    Google Scholar 

  55. Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Bessa EH, Baselga J, Vermorken JB (2004) Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. J Clin Oncol (Meeting Abstracts) 22:5502

    Google Scholar 

  56. Wakelee H, Kelly K (2004) Novel approaches for the treatment of small cell lung cancer. Hematol Oncol Clin North Am 18:499–518

    Google Scholar 

  57. Weiner LM, Carter P (2003) The rollercoaster ride to anti-cancer antibodies. Nat Biotechnol 21:510–511

    Google Scholar 

  58. http://www.corixa.com

  59. http:/www.genmab.com

  60. http:/www.medarex.com

  61. http:/www.merck.de

  62. http:/www.ymbiosciences.com

  63. Zwick E, Bange J, Ullrich A (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8:17–23

    Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor weist auf eine Verbindung mit folgender Firma/Firmen hin: Dr. Axel Hoos ist bei der Biotechnologiefirma Antigenics als Senior Director für Klinische Entwicklung beschäftigt. Antigenics entwickelt Immuntherapien für Krebs und Infektionserkrankungen, insbesondere autologe Vakzine zur Behandlung verschiedener maligner Erkrankungen wie das Nierenzellkarzinom, das maligne Melanom, chronisch myeloische Leukämie und andere. Dr. Hoos hält Aktienoptionen der Firma Antigenics.

Author information

Authors and Affiliations

  1. Sektion Strahlentherapie, Institut für Klinische Radiologie, Universitätsklinikum Mannheim

    F. Lohr

  2. Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Plastische Operationen, Universität Leipzig

    A. Dietz

  3. Clinical Development, Antigenics Inc., New York

    A. Hoos

  4. Sektion Strahlentherapie, Institut für Klinische Radiologie, Universitätsklinikum Mannheim, Theodor-Kutzer-Ufer 1–3, 68167, Mannheim

    F. Lohr

Authors
  1. F. Lohr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Dietz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Hoos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Lohr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lohr, F., Dietz, A. & Hoos, A. Moderne immuntherapeutische Ansätze für die Behandlung von Lungen- und Kopf-Hals-Tumoren. Onkologe 11, 554–570 (2005). https://doi.org/10.1007/s00761-005-0868-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-005-0868-7

Schlüsselwörter

Keywords

Search

Navigation